Acute-on-chronic liver failure (ACLF) represents a critical clinical challenge characterized by rapid functional deterioration and high mortality. While clinicians frequently use granulocyte-colony stimulating factor (G-CSF) to stimulate liver regeneration, its overall efficacy remains controversial in global trials. Recent data from a secondary analysis of the GRAFT trial has identified specific ACLF G-CSF response biomarkers that may finally allow for personalized treatment strategies. These findings suggest that immune profiling can distinguish between patients likely to thrive on G-CSF and those who may not respond favorably.

The Role of VEGF-A in Prognosis

Researchers analyzed blood samples from patients randomized to receive either G-CSF or standard medical therapy. The study utilized an exploratory approach involving univariate and multivariate Cox analyses to determine survival predictors. Notably, baseline plasma levels of Vascular Endothelial Growth Factor A (VEGF-A) emerged as a significant prognostic factor. Patients with specific VEGF-A profiles showed a higher likelihood of transplant-free survival, with an area under the curve (AUC) of 0.70. This suggests that VEGF-A could serve as a reliable baseline tool for clinicians to assess the underlying regenerative potential of the liver before initiating intensive therapies.

Identifying ACLF G-CSF Response Biomarkers via Immune Profiling

Moving beyond general prognosis, the study focused on identifying markers that specifically predict how a patient will react to G-CSF. Using unsupervised hierarchical clustering of immune cell populations, investigators identified a distinct subset of patients who benefited significantly from G-CSF. This specific group achieved a median transplant-free survival of 102 days, compared to just 16 days in other clusters. Furthermore, the expression of CD39 on lymphocytes was identified as a critical metric. Specifically, a higher percentage of CD39-expressing lymphocytes served as an independent predictor of unfavorable outcomes following G-CSF treatment. This finding is vital because it helps prevent the use of G-CSF in patients where the therapy might not provide a survival advantage.

Clinical Implications for Patient Stratification

The ability to select patients prior to treatment could significantly improve the success rates of G-CSF therapy in India and globally. Consequently, immune biomarkers like VEGF-A and CD39 offer a pathway toward precision hepatology. By stratifying patients based on these cellular clusters, medical teams can adapt treatment options for each individual. Although these results are promising, the researchers emphasize that further testing and prospective validation are necessary before these biomarkers can be fully integrated into routine clinical guidelines.

Frequently Asked Questions

What are the primary ACLF G-CSF response biomarkers identified in this study?

The study highlights VEGF-A as a general prognostic marker for survival and CD39 expression on lymphocytes as a specific predictor of G-CSF treatment response. Hierarchical clustering of immune cells also helps identify patient subsets that are more likely to benefit from the therapy.

How does CD39 expression influence G-CSF treatment outcomes?

High CD39 expression on lymphocytes is associated with unfavorable outcomes in patients receiving G-CSF. It acts as an independent predictor of poor transplant-free survival, suggesting that these patients may require alternative therapeutic approaches instead of G-CSF.

Why is VEGF-A significant in ACLF management?

VEGF-A is a marker of angiogenesis and repair. Baseline levels of plasma VEGF-A provide a prognostic indicator of a patient’s transplant-free survival, helping clinicians gauge the severity and potential recovery path of the liver failure.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Splith K et al. Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-study. Hepatol Int. 2026 Mar 07. doi: 10.1007/s12072-026-11069-5. PMID: 41793651.

Thapa S et al. Efficacy of Granulocyte Colony-Stimulating Factor in Acute on Chronic Liver Failure: A Systematic Review and Survival Meta-Analysis. MDPI. 2023 Oct 16. doi: 10.3390/jcm12206558.

Li J et al. The efficacy and safety of granulocyte colony-stimulating factor in the treatment of acute-on-chronic liver failure: A systematic review and meta-analysis. PLOS ONE. 2023 Nov 30. doi: 10.1371/journal.pone.0294155.